These findings reveal that exposure to cancer therapies not only contributes to the expansion of TP53 CH mutations but also associates this expansion with poorer clinical outcomes, highlighting the potential for TP53 mutation monitoring as a prognostic marker in cancer patients undergoing chemoradiation [644]. This evidence concerns the gene TP53 and cancer.